Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status

Abstract Measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy is predictive of early relapse and poor survival. Postremission maintenance therapy that prolongs MRD negativity or converts MRD+ patients to MRD− status may delay or pr... View More